HomeCompareEARS vs O

EARS vs O: Dividend Comparison 2026

EARS yields 65.68% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EARS wins by $823.3K in total portfolio value
10 years
EARS
EARS
● Live price
65.68%
Share price
$3.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$857.5K
Annual income
$214,640.91
Full EARS calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — EARS vs O

📍 EARS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEARSO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EARS + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EARS pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EARS
Annual income on $10K today (after 15% tax)
$5,582.92/yr
After 10yr DRIP, annual income (after tax)
$182,444.77/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, EARS beats the other by $178,107.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EARS + O for your $10,000?

EARS: 50%O: 50%
100% O50/50100% EARS
Portfolio after 10yr
$445.9K
Annual income
$109,871.82/yr
Blended yield
24.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

EARS
No analyst data
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EARS buys
0
O buys
14
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$O▲ Buy$1,001 - $15,0002025-08-05
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002024-02-13
Ro Khanna🏢 House$O▼ Sell$1,001 - $15,0002023-11-03
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-10-31
Ro Khanna🏢 House$O▼ Sell$1,001 - $15,0002023-09-06
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-08-29
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-06-29
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-06-26
Ro Khanna🏢 House$O▼ Sell$1,001 - $15,0002023-05-19
Gary Peters🏛 Senate$O▲ Buy$15,001 - $50,0002023-03-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEARSO
Forward yield65.68%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$857.5K$34.2K
Annual income after 10y$214,640.91$5,102.74
Total dividends collected$722.8K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: EARS vs O ($10,000, DRIP)

YearEARS PortfolioEARS Income/yrO PortfolioO Income/yrGap
1← crossover$17,268$6,568.14$10,818$608.16+$6.5KEARS
2$29,077$10,599.97$11,787$741.68+$17.3KEARS
3$47,793$16,681.04$12,946$911.00+$34.8KEARS
4$76,764$25,624.68$14,345$1,127.94+$62.4KEARS
5$120,602$38,464.70$16,056$1,409.05+$104.5KEARS
6$185,521$56,477.71$18,171$1,777.83+$167.3KEARS
7$279,704$81,195.93$20,820$2,268.21+$258.9KEARS
8$413,691$114,407.58$24,188$2,929.90+$389.5KEARS
9$600,792$158,142.40$28,533$3,837.11+$572.3KEARS
10$857,488$214,640.91$34,235$5,102.74+$823.3KEARS

EARS vs O: Complete Analysis 2026

EARSStock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Full EARS Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this EARS vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EARS vs SCHDEARS vs JEPIEARS vs KOEARS vs MAINEARS vs STAGEARS vs ADCEARS vs NNNEARS vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.